NuvOx Pharma has been issued a patent covering NuvOx core technology of dodecafluoropentane emulsion. US Patent No. 8,822,549, issued on September 4, 2014, entitled, “Buffered Oxygen Therapeutic,” has claims for buffered formulations of dodecafluoropentane emulsion (DDFPe).
Evan Unger, MD, President and CEO of NuvOx Pharma announced today that NuvOx has been issued a patent covering NuvOx core technology of dodecafluoropentane emulsion. US Patent No. 8,822,549, issued on September 4, 2014, entitled, “Buffered Oxygen Therapeutic,” has claims for buffered formulations of dodecafluoropentane emulsion (DDFPe). NuvOx is developing DDFPe as an oxygen therapeutic. NVX-108 is NuvOx lead oxygen therapeutic product, and is currently in Phase Ib clinical trials. In this trial, brain cancer patients are receiving doses of NVX-108 during each radiation treatment to increase tumor oxygen and hopefully improve the response to radiation therapy. DDFPe was originally tested as a contrast agent in 2,200 patients and was approvable by the US FDA and approved in Europe but never launched due to the small size of the contrast agent market.
After discovering that DDFPe was highly effective at transporting oxygen, NuvOx licensed the patents and obtained ownership of the regulatory documents. The original formulation of DDFPe was not buffered. NuvOx developed a buffered formulation conferring greater stability to the product. US Patent No. 8,822,549 has claims covering buffered formulations. Dr. Unger said, “We are pleased to receive this patent, as the composition of matter claims protect our product and enhance its commercialization.” NuvOx is a privately held company based in Tucson, Arizona.
For further information see http://www.nuvoxpharma.com.
Editors Note: NuvOx Pharma will be presenting to accredited investors at the White Hat Life Science Investor Conference at the Hyatt Regency Phoenix on September 17, 2014. For program details and registration information visit www.WhiteHatInvestors.com.